Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Theravance Biopharma (TBPH) over the last 12 years, with Q3 2025 value amounting to -$107.2 million.

  • Theravance Biopharma's Net Cash Flow fell 36655.64% to -$107.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $151.4 million, marking a year-over-year increase of 41340.18%. This contributed to the annual value of -$1.7 million for FY2024, which is 9932.41% up from last year.
  • As of Q3 2025, Theravance Biopharma's Net Cash Flow stood at -$107.2 million, which was down 36655.64% from $171.3 million recorded in Q2 2025.
  • Over the past 5 years, Theravance Biopharma's Net Cash Flow peaked at $331.2 million during Q3 2022, and registered a low of -$120.4 million during Q4 2022.
  • In the last 5 years, Theravance Biopharma's Net Cash Flow had a median value of -$7.5 million in 2024 and averaged $3.4 million.
  • In the last 5 years, Theravance Biopharma's Net Cash Flow tumbled by 301421.41% in 2023 and then soared by 238722.3% in 2025.
  • Quarter analysis of 5 years shows Theravance Biopharma's Net Cash Flow stood at -$34.3 million in 2021, then tumbled by 251.16% to -$120.4 million in 2022, then soared by 73.3% to -$32.1 million in 2023, then soared by 144.86% to $14.4 million in 2024, then crashed by 843.14% to -$107.2 million in 2025.
  • Its Net Cash Flow was -$107.2 million in Q3 2025, compared to $171.3 million in Q2 2025 and $72.8 million in Q1 2025.